Hospital
Elk Regional Health Center
Elk Regional Health Center was paid $2.21M by Medicaid between Feb 2018 and Nov 2024, across 152 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoELK REGIONAL HEALTH CENTER
SAINT MARYS, PA 15857
SAINT MARYS, PA 15857
33aNPI1326434242assigned 04/07/2015
33bProvider typeCritical Access Hospital
28Total paid$2.21M
24GClaims70,140
24DCodes billed152
24AFirst – last monthFeb 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Pennsylvania
Rank by total paid#3 of 12
Median peer was paid$1.19M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13 | $798.12 | |
| 2019 | 371 | $14K | |
| 2020 | 7,531 | $173K | |
| 2021 | 40,004 | $1.09M | |
| 2022 | 8,056 | $372K | |
| 2023 | 7,534 | $305K | |
| 2024incomplete | 6,631 | $253K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 3,690 | 3,537 | $424K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 5,499 | 5,328 | $422K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 1,757 | 1,649 | $269K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 5.4% | 2,684 | 794 | $120K |
| 87631 | 4.0% | 632 | 621 | $89K | |
| 80053 | Comprehensive metabolic panel | 2.2% | 5,036 | 4,504 | $48K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 250 | 240 | $44K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.7% | 1,009 | 982 | $39K |
| 80050 | General health panel | 1.7% | 779 | 760 | $37K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 6,551 | 5,774 | $33K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 376 | 371 | $32K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.2% | 897 | 892 | $27K |
140 more codes
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.2% | 771 | $26K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 857 | $23K |
| X0620 | 1.0% | 100 | $23K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 187 | $19K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 232 | $18K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 371 | $18K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 228 | $17K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,013 | $17K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 606 | $17K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 225 | $16K |
| 76830 | Ultrasound, transvaginal | <1% | 344 | $16K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 192 | $15K |
| 80061 | Lipid panel | <1% | 1,087 | $14K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 805 | $14K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 324 | $14K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 690 | $13K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 59 | $13K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 531 | $13K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 531 | $13K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 259 | $12K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 327 | $10K |
| 82607 | <1% | 742 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,077 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 46 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,098 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 594 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,082 | $7K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 144 | $7K |
| 81001 | <1% | 2,690 | $7K | |
| 76536 | <1% | 145 | $7K | |
| 0002A | <1% | 162 | $7K | |
| 83735 | <1% | 1,117 | $7K | |
| 84484 | <1% | 846 | $7K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 40 | $7K |
| 84439 | <1% | 765 | $6K | |
| 82728 | <1% | 526 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 480 | $6K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 172 | $6K |
| 86618 | <1% | 224 | $5K | |
| 84702 | <1% | 289 | $5K | |
| 0001A | <1% | 164 | $5K | |
| 80076 | <1% | 553 | $5K | |
| 84703 | <1% | 446 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 739 | $5K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 226 | $5K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 294 | $4K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 79 | $4K |
| 87040 | <1% | 238 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 18 | $4K |
| 85730 | <1% | 701 | $4K | |
| 76641 | <1% | 69 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 156 | $4K |
| 87081 | <1% | 705 | $4K | |
| 85027 | <1% | 563 | $4K | |
| 87186 | <1% | 393 | $3K | |
| 73564 | <1% | 154 | $3K | |
| 83540 | <1% | 419 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 346 | $3K |
| 83605 | <1% | 465 | $3K | |
| 72110 | <1% | 149 | $3K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 155 | $3K |
| 82570 | <1% | 434 | $3K | |
| 82043 | <1% | 382 | $3K | |
| 83690 | <1% | 639 | $3K | |
| 72141 | <1% | 13 | $3K | |
| 85610 | <1% | 859 | $3K | |
| 87077 | <1% | 341 | $3K | |
| 84550 | <1% | 383 | $2K | |
| 83880 | <1% | 85 | $2K | |
| 80320 | <1% | 179 | $2K | |
| 97161 | <1% | 41 | $2K | |
| 94729 | <1% | 71 | $2K | |
| 73610 | <1% | 99 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 45 | $2K |
| 94726 | <1% | 70 | $2K | |
| 93971 | <1% | 25 | $2K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 194 | $2K |
| 73030 | <1% | 102 | $2K | |
| 82784 | <1% | 53 | $2K | |
| 73630 | <1% | 136 | $2K | |
| 97162 | <1% | 24 | $1K | |
| 83550 | <1% | 292 | $1K | |
| 86850 | <1% | 180 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 109 | $1K |
| 86038 | <1% | 84 | $1K | |
| 85652 | <1% | 427 | $1K | |
| 71250 | <1% | 25 | $1K | |
| 85379 | <1% | 106 | $1K | |
| 86140 | <1% | 387 | $1K | |
| 80081 | <1% | 12 | $978.98 | |
| 86787 | <1% | 50 | $918.95 | |
| 73130 | <1% | 76 | $916.85 | |
| 82565 | <1% | 166 | $877.81 | |
| 94060 | <1% | 99 | $871.15 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $826.25 |
| 87797 | <1% | 38 | $808.64 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 24 | $765.31 |
| 83655 | <1% | 65 | $716.55 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 104 | $677.25 |
| 86592 | <1% | 179 | $673.61 | |
| 84153 | <1% | 27 | $617.80 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 16 | $614.88 |
| 73110 | <1% | 51 | $569.92 | |
| 86431 | <1% | 65 | $486.29 | |
| 83001 | <1% | 25 | $421.75 | |
| 93017 | <1% | 12 | $375.42 | |
| 72052 | <1% | 12 | $357.50 | |
| 86901 | <1% | 106 | $355.50 | |
| 86900 | <1% | 106 | $350.88 | |
| 84403 | <1% | 14 | $324.00 | |
| 81025 | <1% | 79 | $303.49 | |
| 84460 | <1% | 45 | $299.52 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 34 | $247.50 |
| 81003 | <1% | 80 | $226.70 | |
| 80329 | <1% | 28 | $217.92 | |
| 84450 | <1% | 28 | $195.15 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 724 | $171.07 |
| 82746 | <1% | 14 | $142.80 | |
| 96376 | <1% | 148 | $128.88 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 240 | $114.29 |
| 82248 | <1% | 19 | $106.68 | |
| 87070 | <1% | 15 | $106.26 | |
| J2704 | Injection, propofol, 10 mg | <1% | 30 | $96.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 98 | $91.23 |
| 82550 | <1% | 12 | $79.10 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 359 | $47.37 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 21 | $37.13 |
| 0353U | <1% | 14 | $32.51 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 475 | $29.63 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 198 | $29.60 |
| 36415 | Collection of venous blood by venipuncture | <1% | 719 | $15.91 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 149 | $13.56 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 33 | $6.48 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 36 | $6.02 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 30 | $3.72 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 56 | $1.82 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14 | $1.29 |
| A9270 | Non-covered item or service | 0% | 38 | $0.00 |
| 87581 | 0% | 21 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 169 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHAPMAN, BRADLEY (PRESIDENT)
Parent organizationPENN HIGHLANDS HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Olean General Hospital | Olean, NY | $638K |
| Olean General Hospital | Bradford, PA | $241K |
| Bradford Regional Medical Services | Bradford, PA | $67K |
| Elk Regional Professional Group, INC | Saint Marys, PA | $20K |
| Elk Regional Health Center | Emporium, PA | $13K |
| Olean General Hospital | Bradford, PA | $10K |
| Elk Regional Health Center | Johnsonburg, PA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.